CSL faces shareholder class action, and CSL stock is valued at AUD 94.4 billion

Published on 10/23/2026 at 10:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Deborah Waterhouse starts on February 1, 2027 after CSL's CEO search. CSL stock trades at EUR 121.90 on October 23, 2026, while CSL is valued at AUD 94.4 billion.

Leadership and legal pressure

A shareholder class action was reported on October 23, 2026, after a USD 5.00 billion impairment linked to Vifor Pharma.
Deborah Waterhouse is scheduled to become CEO on February 1, 2027.
CSL stock trades at EUR 121.90 at 10:06 a.m. CEST at Lang & Schwarz on October 23, 2026.

CSL, AU000000CSL8, Illustration mit AI erstellt.

CSL (ISIN AU000000CSL8) is trading at EUR 121.90 at Lang & Schwarz on October 23, 2026 at 10:06 a.m. CEST. The company faces a shareholder class action over past earnings guidance, while its incoming CEO Deborah Waterhouse is due to take office on February 1, 2027.

According to Reuters on October 22, 2026, the case alleges that CSL breached disclosure rules when it cut its earnings outlook. The report linked the dispute to a USD 5.00 billion impairment charge related to Vifor Pharma, acquired in 2022 for USD 12.00 billion. CSL said it complied with its disclosure obligations and would defend the case.

Three events reshape the story

The recent chronology points to a company managing both expansion and financial scrutiny. On October 5, 2026, CSL announced a global partnership with Alentis Therapeutics that included a USD 355.00 million upfront payment and up to USD 1.20 billion in commercial milestones, according to CSL. On October 21, 2026, the company appointed Waterhouse as CEO from February 1, 2027, according to CSL. The shareholder case was reported on October 23, 2026.

What dates matter next?

CSL's investor calendar identifies the 2026 annual general meeting for October 27, 2026, in Melbourne and online, according to the company's investor relations page. The second key date is February 1, 2027, when Waterhouse is scheduled to begin as CEO.

What does the legal case mean?

The central investor issue is the distance between reported underlying operations and the cost of correcting earlier assumptions. CSL's Australian listing was last at AUD 196.70 on October 23, 2026 at 4:10 p.m. AEDT, while its market capitalization was AUD 94.4 billion. The same quote showed a 52-week range of AUD 90.00 to AUD 221.49, placing the latest Australian price below the yearly high but above the yearly low.

Leadership change meets litigation

Waterhouse gives CSL a named transition plan, but the legal dispute keeps disclosure quality and the Vifor-related impairment central to the investment case. The October 27 meeting is the next formal setting for management and shareholder questions.

At Lang & Schwarz, CSL stock was trading at EUR 121.90 on October 23, 2026 at 10:06 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of CSL stock.